ReviewViruses2018
The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
Review in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A comprehensive investigation of the anion inhibition profile of a β-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Article
- Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein.Viruses · 2024Article
- Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases.Pharmaceutics · 2023Review
- From Genetics to Epigenetics: Top 4 Aspects for Improved SARS-CoV-2 Vaccine Designs as Paradigmatic Examples.Global medical genetics · 2022Review
- Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients.Scientific reports · 2021Article
- Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors.Frontiers in molecular biosciences · 2021Review
- The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals.PLoS pathogens · 2020Article
- Stabilized diverse HIV-1 envelope trimers for vaccine design.Emerging microbes & infections · 2020Article
- A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria.International journal of biological macromolecules · 2020Article
- Antigenic Variability.Frontiers in immunology · 2020Article
- Review
- A Modular Vaccine Platform Combining Self-Assembled Peptide Cages and Immunogenic Peptides.Advanced functional materials · 2019Article
- Antiretroviral drug-S for a possible HIV elimination.International journal of physiology, pathophysiology and pharmacology · 2019Article
- Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.Journal of immunology research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although effective antibody-based vaccines have been developed against multiple viruses, such approaches have so far failed for the human immunodeficiency virus type 1 (HIV-1). Despite the success of anti-retroviral therapy (ART) that has turned HIV-1 infection into a chronic disease and has reduced the number of new infections worldwide, a vaccine against HIV-1 is still urgently needed. We discuss here the major reasons for the failure of "classical" vaccine approaches, which are mostly due to the biological properties of the virus itself. HIV-1 has developed multiple mechanisms of immune escape, which also account for vaccine failure. So far, no vaccine candidate has been able to induce broadly neutralizing antibodies (bnAbs) against primary patient viruses from different clades. However, such antibodies were identified in a subset of patients during chronic infection and were shown to protect from infection in animal models and to reduce viremia in first clinical trials. Their detailed characterization has guided structure-based reverse vaccinology approaches to design better HIV-1 envelope (Env) immunogens. Furthermore, conserved Env epitopes have been identified, which are promising candidates in view of clinical applications. Together with new vector-based technologies, considerable progress has been achieved in recent years towards the development of an effective antibody-based HIV-1 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.